

**Amendments to the CLAIMS:**

1. – 29. (cancelled).

30. (currently amended) [[The]] An azabicyclic derivative of ~~claim 29~~, which is  
 2,2'-Bis-((±)-1-aza-bicyclo[2.2.2]oct-3-yloxy)-[5,5']-bithiazolyl;  
 2,2'-Bis-((±)-1-aza-bicyclo[2.2.2]oct-3-yloxy)-[5,5']-bifuranyl;  
 6,6'-Bis-((±)-1-aza-bicyclo[2.2.2]oct-3-yloxy)-[3,3']-bipyridinyl;  
 6,6'-Bis-((±)-1-aza-bicyclo[2.2.2]oct-3-yloxy)-[3,3']-bipyridazinyl; or  
 6-[4-(1-Aza-bicyclo[2.2.2]oct-3-yloxy)-phenyl]-pyridazin-3-ol-(1-aza-bicyclo[2.2.2]oct-3-yl);  
 or an enantiomer thereof, or a mixture of its enantiomers, or a pharmaceutically-acceptable  
 addition salt thereof, or an onium salt thereof.


31. (cancelled).

32. (currently amended) [[The]] An azabicyclic derivative of ~~claim 31~~, which is  
 6,6'-Bis-[1,4]-diazabicyclo[3.2.2]nonan-1-yl-[3,3']-bipyridazinyl;  
 1,2-Di-[6-(1,4-diazabicyclo[3.2.2]nonan-4-yl)-pyridazin-3-yl-thio]-benzene; or  
 1,3-Di-[6-(1,4-diazabicyclo[3.2.2]nonan-4-yl)-pyridazin-3-yl-thio]-benzene;  
 or an enantiomer thereof, or a mixture of its enantiomers, or a pharmaceutically-acceptable  
 addition salt thereof, or an onium salt thereof.

33. – 42. (cancelled).

43. (cancelled).


44. (previously presented) An azabicyclic derivative represented by Formula I




an enantiomer thereof, or a mixture of its enantiomers, or a pharmaceutically-acceptable addition

salt thereof, or an onium salt thereof, wherein,

AZA represents an azacyclic group selected from




and



wherein n is 0, 1, 2 or 3 and m is 1 or 2; X' and X'' are absent (i.e. represent single (covalent) bonds); or X' and X'' represent -O-, -S-, -SO-, -NH-, or -(CO)-; and A' and A'' represent phenyl, pyridyl, thienyl, furanyl, pyridazinyl and/or thiazolyl; and Y', Y'' and L represent single (covalent) bonds; or Y' and Y'' represent -O-, -S-, -SO- or -NH-; and L represents a phenyl group.


45. (withdrawn - currently amended) The compound of claim 44, an enantiomer thereof, or a mixture of its enantiomers, or a pharmaceutically-acceptable addition salt thereof, or an onium salt thereof, wherein AZA represents an the azacyclic group ~~selected from~~



wherein n is 1 and m is 1; X' and X'' are absent (i.e. represent single (covalent) bonds); and A' and A'' represent pyridazinyl; and Y', Y'' and L represent single (covalent) bonds.



46. (previously presented) The compound of claim 44, which is 6,6'-bis-[1,4]-diazabicyclo[3.2.2]nonan-1-yl-[3,3']-bipyridazinyl, or an enantiomer thereof, or a mixture of its enantiomers, or a pharmaceutically-acceptable addition salt thereof, or an onium salt thereof.

47. (new) An azabicyclic derivative represented by Formula I



an enantiomer thereof, or a mixture of its enantiomers, or a pharmaceutically-acceptable addition salt thereof, or an onium salt thereof, wherein,


AZA represents an azacyclic group selected from




wherein n is 1 and m is 2; X' and X'' represent single (covalent) bonds; A' and A'' represent pyridazinyl or thiazolyl; and Y', Y'', and L represent single (covalent) bonds.

48. (new) The azabicyclic derivative of claim 47, wherein,

AZA represents the azacyclic group




49. (new) An azabicyclic derivative represented by Formula I



an enantiomer thereof, or a mixture of its enantiomers, or a pharmaceutically-acceptable addition salt thereof, or an onium salt thereof, wherein,


AZA represents an azacyclic group selected from



wherein n is 1 and m is 2; X' and X'' represent single (covalent) bonds; A' and A'' represent pyridazinyl or thiazolyl; Y' and Y'' represent -O-, -S-, -SO-, or -NH-; and L represents a phenyl group.

50. (new) The azabicyclic derivative of claim 49, wherein,

AZA represents the azacyclic group



51. (new) The azabicyclic derivative of claim 50, wherein Y' and Y'' represent -O- or -S-.

52. (new) The azabicyclic derivative of claim 51, wherein A' and A'' represent pyridazinyl.